{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:51Z","timestamp":1788922131443,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rural states have experienced increasing injection drug use (IDU)-associated infective endocarditis (IE). Inpatient addiction consult services can reduce morbidity associated with substance use and other infectious complications, such as IDU-IE. However data on the impact of such services on healthcare utilization are limited, particularly in rural communities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study assesses clinical and health service utilization data from index hospitalizations for IDU-IE before and after the implementation of the Integrated Medication for Addiction Treatment (IMAT) program at a tertiary care center in a rural state. We summarized data descriptively, stratified by both pre- and post-IMAT program implementation and IDU-IE and non-IDU IE. We also performed exploratory multivariable analyses assessing the association between IMAT program implementation and various outcomes. The primary outcomes were: 1) 90-day emergency department (ED) visits and 2) 30-day hospital readmissions post-discharge. Secondary outcomes included prescriptions at time of discharge for medication for opioid use disorder (MOUD), naloxone and key vaccinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified <jats:italic>n<\/jats:italic>\u2009=\u200999 patients with IDU-IE. Comparing pre- and post-IMAT implementation, 30-day readmissions trended lower post-IMAT (18%) versus pre-IMAT (22%), although the difference was not significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.7). 90-day ED visits remained stable (37%, <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.9). The proportion of MOUD prescribing (24% versus 80%), hepatitis B vaccination (29% versus 51%), and Tdap vaccination (7.3% versus 41%) increased significantly following IMAT implementation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>p<\/jats:italic>\u2009=\u20090.037 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively). In a regression analysis controlling for age, housing status, primary care provider, age, hepatitis C, cardiac device, Duke\u2019s criteria, valve affected, alcohol use disorder, payer, and vascular or infectious complications, the IMAT program was not significantly associated with the primary outcomes or with hepatitis B vaccination. However, the IMAT program was associated with increased MOUD prescribing (aOR: 110; CI:16\u20131500), naloxone prescribing (aOR 18; CI: 1.1\u20131600) hepatitis A vaccination (aOR: 5.3; CI: 1.2\u201332), and Tdap vaccination (aOR: 9.2; CI: 2.0\u201359).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Inpatient addiction services were associated with increased prescribing of MOUD, naloxone and key vaccinations, though the incidence of acute healthcare utilization did not change. These results highlight hospitalization as an opportunity to connect patients with IDU-IE to MOUD and preventative care, particularly in rural areas where access to such services may be limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00614-6","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:48:37Z","timestamp":1760615317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inpatient addiction care is associated with increased vaccinations, medication for opioid use disorder and naloxone prescribing among patients with infective endocarditis in a rural state"],"prefix":"10.1186","volume":"20","author":[{"given":"Eva J.","family":"Farkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Mohoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Schaumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"McAuliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinna","family":"Thakarar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"1","key":"614_CR1","first-page":"51","volume":"4","author":"MG Hofmeister","year":"2022","unstructured":"Hofmeister MG, Asher A, Jones CM, Augustine RJ, Burkholder C, Collins J, et al. Prevalence and types of drugs used among hepatitis a patients during outbreaks associated with person-to-person transmission, Kentucky, Michigan, and West Virginia, 2016-2019. J Appalach Health. 2022;4(1):51\u201360.","journal-title":"J Appalach Health"},{"issue":"3","key":"614_CR2","doi-asserted-by":"publisher","first-page":"ofab613","DOI":"10.1093\/ofid\/ofab613","volume":"9","author":"EM Pichlinski","year":"2022","unstructured":"Pichlinski EM, Hoff E, Epperson LC, Morley E, Cao JD, Thoppil J, et al. Tetanus: a rare complication of black tar heroin use. Open Forum Infect Dis. 2022, Mar;9(3):ofab613.","journal-title":"Open Forum Infect Dis"},{"issue":"19","key":"614_CR3","doi-asserted-by":"publisher","first-page":"e012969","DOI":"10.1161\/JAHA.119.012969","volume":"8","author":"AN Kadri","year":"2019","unstructured":"Kadri AN, Wilner B, Hernandez AV, Nakhoul G, Chahine J, Griffin B, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc. 2019, Oct;8(19):e012969.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"614_CR4","doi-asserted-by":"publisher","first-page":"e0271510","DOI":"10.1371\/journal.pone.0271510","volume":"17","author":"R Bhandari","year":"2022","unstructured":"Bhandari R, Alexander T, Annie FH, Kaleem U, Irfan A, Balla S, et al. Steep rise in drug use-associated infective endocarditis in West Virginia: characteristics and healthcare utilization. PLoS One. 2022;17(7):e0271510.","journal-title":"PLoS One"},{"issue":"6","key":"614_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.amjms.2016.08.010","volume":"352","author":"L Hartman","year":"2016","unstructured":"Hartman L, Barnes E, Bachmann L, Schafer K, Lovato J, Files DC. Opiate injection-associated infective endocarditis in the Southeastern United States. Am J Med Sci. 2016, Dec;352(6):603\u201308.","journal-title":"Am J Med Sci"},{"issue":"1","key":"614_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12879-018-3408-y","volume":"18","author":"ME Gray","year":"2018","unstructured":"Gray ME, Rogawski McQuade ET, Scheld WM, Dillingham RA. Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study. BMC Infect Dis. 2018, Oct, 24;18(1):532.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"614_CR7","doi-asserted-by":"publisher","first-page":"ofaa045","DOI":"10.1093\/ofid\/ofaa045","volume":"7","author":"EK Nenninger","year":"2020","unstructured":"Nenninger EK, Carwile JL, Ahrens KA, Armstrong B, Thakarar K. Rural-Urban differences in hospitalizations for opioid use-associated infective endocarditis in the United States, 2003-2016. Open Forum Infect Dis. 2020, Feb;7(2):ofaa045.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"614_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12954-021-00524-1","volume":"18","author":"K Thakarar","year":"2021","unstructured":"Thakarar K, Sankar N, Murray K, Lucas FL, Burris D, Smith RP. Injections and infections: understanding syringe service program utilization in a rural state. Harm Reduct J. 2021, Jul, 17;18(1):74.","journal-title":"Harm Reduct J"},{"issue":"9403","key":"614_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0140-6736(03)15266-X","volume":"363","author":"P Moreillon","year":"2004","unstructured":"Moreillon P, Que YA. Infective endocarditis. Lancet. 2004, Jan, 10;363(9403):139\u201349.","journal-title":"Lancet"},{"issue":"7","key":"614_CR10","doi-asserted-by":"publisher","first-page":"e185220","DOI":"10.1001\/jamanetworkopen.2018.5220","volume":"1","author":"L Rodger","year":"2018","unstructured":"Rodger L, Glockler-Lauf SD, Shojaei E, Sherazi A, Hallam B, Koivu S, et al. Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open. 2018, Nov, 2;1(7):e185220.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"614_CR11","doi-asserted-by":"publisher","first-page":"e012465","DOI":"10.1161\/JAHA.119.012465","volume":"9","author":"M Mori","year":"2020","unstructured":"Mori M, Brown KJ, Bin Mahmood SU, Geirsson A, Mangi AA. Trends in infective endocarditis hospitalizations, characteristics, and valve operations in patients with opioid use disorders in the United States: 2005-2014. J Am Heart Assoc. 2020, Mar, 17;9(6):e012465.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"614_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.athoracsur.2020.03.089","volume":"110","author":"A Geirsson","year":"2020","unstructured":"Geirsson A, Schranz A, Jawitz O, Mori M, Feng L, Zwischenberger BA, et al. The evolving burden of drug use associated infective endocarditis in the United States. The Ann Of Thorac Surg. 2020, Oct, 1;110(4):1185\u201392.","journal-title":"The Ann Of Thorac Surg"},{"issue":"3","key":"614_CR13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jtcvs.2016.02.072","volume":"152","author":"JB Kim","year":"2016","unstructured":"Kim JB, Ejiofor JI, Yammine M, Ando M, Camuso JM, Youngster I, et al. Surgical outcomes of infective endocarditis among intravenous drug users. J Thorac Cardiovasc Surg. 2016, Sep;152(3):832\u201341.e1.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"614_CR14","doi-asserted-by":"publisher","first-page":"e0225460","DOI":"10.1371\/journal.pone.0225460","volume":"14","author":"K Thakarar","year":"2019","unstructured":"Thakarar K, Rokas KE, Lucas FL, Powers S, Andrews E, DeMatteo C, et al. Mortality, morbidity, and cardiac surgery in injection drug use (IDU)-associated versus non-IDU infective endocarditis: the need to expand substance use disorder treatment and harm reduction services. PLoS One. 2019;14(11):e0225460.","journal-title":"PLoS One"},{"issue":"10","key":"614_CR15","doi-asserted-by":"publisher","first-page":"ofz396","DOI":"10.1093\/ofid\/ofz396","volume":"6","author":"L Rodger","year":"2019","unstructured":"Rodger L, Shah M, Shojaei E, Hosseini S, Koivu S, Silverman M. Recurrent endocarditis in persons who inject drugs. Open Forum Infect Dis. 2019, Oct;6(10):ofz396.","journal-title":"Open Forum Infect Dis"},{"key":"614_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jss.2022.10.004","volume":"282","author":"AY Nodoushani","year":"2023","unstructured":"Nodoushani AY, Wang Y, Datar Y, Mohnot J, Karlson KJ, Edwards NM, et al. Association of intravenous drug use and length of stay following infective endocarditis. J Surg Res. 2023, Feb;282:239\u201345.","journal-title":"J Surg Res"},{"issue":"8","key":"614_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","volume":"174","author":"JM Liebschutz","year":"2014","unstructured":"Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014, Aug, 1;174(8):1369\u201376.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"614_CR18","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s11606-019-05251-9","volume":"34","author":"H Englander","year":"2019","unstructured":"Englander H, Dobbertin K, Lind BK, Nicolaidis C, Graven P, Dorfman C, et al. Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis. J Gen Intern Med. 2019, Dec;34(12):2796\u2013803.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"614_CR19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/cid\/ciy924","volume":"68","author":"LR Marks","year":"2019","unstructured":"Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019, May, 17;68(11):1935\u201337.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"614_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/ADM.0000000000000725","volume":"15","author":"NS Nolan","year":"2021","unstructured":"Nolan NS, Marks LR, Liang SY, Durkin MJ. Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection. J Addict Med. 2021, Apr, 1;15(2):155\u201358.","journal-title":"J Addict Med"},{"issue":"6","key":"614_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.psym.2020.06.019","volume":"61","author":"V Ray","year":"2020","unstructured":"Ray V, Waite MR, Spexarth FC, Korman S, Berget S, Kodali S, et al. Addiction management in hospitalized patients with intravenous drug use-associated infective endocarditis. Psychosomatics. 2020, Dec;61(6):678\u201387.","journal-title":"Psychosomatics"},{"issue":"5","key":"614_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","volume":"129","author":"ES Rosenthal","year":"2016","unstructured":"Rosenthal ES, Karchmer AW, Theisen-Toupal J, Castillo RA, Rowley CF. Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis. Am J Med. 2016, May;129(5):481\u201385.","journal-title":"Am J Med"},{"issue":"11","key":"614_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.amjmed.2020.04.025","volume":"133","author":"SJ Wang","year":"2020","unstructured":"Wang SJ, Wade E, Towle J, Hachey T, Rioux J, Samuels O, et al. Effect of inpatient medication-assisted therapy on against-medical-advice discharge and readmission rates. Am J Med. 2020, Nov;133(11):1343\u201349.","journal-title":"Am J Med"},{"key":"614_CR24","doi-asserted-by":"publisher","unstructured":"Ramirez V. Injection drug use and care charges for infective endocarditis. J Educ Chang Maine Med Cent [Internet]. 2020;2(1). Available fromhttps:\/\/knowledgeconnection.mainehealth.org\/jmmc\/vol2\/iss1\/12https:\/\/doi.org\/10.46804\/2641-2225.1029.","DOI":"10.46804\/2641-2225.1029"},{"issue":"1","key":"614_CR25","doi-asserted-by":"publisher","first-page":"e0263156","DOI":"10.1371\/journal.pone.0263156","volume":"17","author":"TD Brothers","year":"2022","unstructured":"Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS One. 2022;17(1):e0263156.","journal-title":"PLoS One"},{"issue":"19","key":"614_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6619a1","volume":"66","author":"K Mack","year":"2017","unstructured":"Mack K, Jones C, Ballesteros M. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas - United States. MMWR Surveill Summ. 2017;66(19):1\u201312.","journal-title":"MMWR Surveill. Summ"},{"issue":"11","key":"614_CR27","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s11606-022-07618-x","volume":"37","author":"H Englander","year":"2022","unstructured":"Englander H, Jones A, Krawczyk N, Patten A, Roberts T, Korthuis PT, et al. A taxonomy of hospital-based addiction care models: a scoping review and key informant interviews. J Gen Intern Med. 2022, Aug;37(11):2821\u201333.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"614_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/313753","volume":"30","author":"JS Li","year":"2000","unstructured":"Li JS, Sexton DJ, Mick N, Nettles R, Fowler VGJ, Ryan T, et al. Proposed modifications to the duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000, Apr;30(4):633\u201338.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"614_CR29","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020, Feb, 5;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"614_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.athoracsur.2019.11.011","volume":"110","author":"Z Tyerman","year":"2020","unstructured":"Tyerman Z, Shah S, Mehaffey JH, Wanchek T, Hawkins RB, Rogawski McQuade ET, et al. Cost-effectiveness of postoperative drug rehabilitation for injection drug users. Ann Thorac Surg. 2020, Aug;110(2):492\u201399.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"614_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11606-016-3919-4","volume":"32","author":"CM Velez","year":"2017","unstructured":"Velez CM, Nicolaidis C, Korthuis PT, Englander H. \u201cIt\u2019s been an experience, a life learning experience\u201d: a qualitative study of hospitalized patients with substance use disorders. J Gen Intern Med. 2017, Mar;32(3):296\u2013303.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"614_CR32","first-page":"752","volume":"13","author":"H Englander","year":"2018","unstructured":"Englander H, Collins D, Perry SP, Rabinowitz M, Phoutrides E, Nicolaidis C. \u201cWe\u2019ve learned it\u2019s a medical illness, not a moral choice\u201d: qualitative study of the effects of a multicomponent addiction intervention on hospital providers\u2019 attitudes and experiences. J Hosp Med. 2018, Nov, 1;13(11):752\u201358.","journal-title":"J Hosp Med"},{"key":"614_CR33","first-page":"204993612311970","volume":"10","author":"A Eckland","year":"2023","unstructured":"Eckland A, Kohut M, Stoddard H, Burris D, Chessa F, Sikka MK, et al. \u201cI know my body better than anyone else\u201d: a qualitative study of perspectives of people with lived experience on antimicrobial treatment decisions for injection drug use-associated infections. Ther Adv Infect Dis. 2023, Dec;10:20499361231197065.","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"614_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/ADM.0000000000000819","volume":"16","author":"C King","year":"2022","unstructured":"King C, Collins D, Patten A, Nicolaidis C, Englander H. Trust in hospital physicians among patients with substance use disorder referred to an addiction consult service: a mixed-methods study. J Addict Med. 2022, Feb, 1;16(1):41\u201348.","journal-title":"J Addict Med"},{"issue":"5","key":"614_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00614-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:48:39Z","timestamp":1760615319000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00614-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00614-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the MaineHealth IRB Protocol #48829.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No footnotes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Footnotes"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}